SCHEDULE: Cormorant Asset Management Discloses 5.69% Stake in BioAge Labs

Cormorant Asset Management, LP and Bihua Chen have reported a 5.69% beneficial ownership stake in BioAge Labs, Inc. common stock as of December 31, 2025.

Summary

• Cormorant Asset Management, LP and Bihua Chen collectively beneficially own 2,040,605 shares of BioAge Labs, Inc. common stock.
• This ownership represents 5.69% of the issuer's outstanding common stock.
• The percentage is calculated based on 35,855,037 shares of common stock outstanding as of October 31, 2025, as reported in BioAge Labs' Form 10-Q.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of BioAge Labs, Inc.
• Cormorant Asset Management, LP serves as the investment adviser to certain funds (the "Cormorant Funds"), which directly hold these shares.
• Bihua Chen is also a reporting person with respect to the shares held by the Cormorant Funds.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the continued disclosure of a significant beneficial ownership stake by a specialized asset manager like Cormorant Asset Management suggests ongoing confidence in BioAge Labs, Inc.

Positives

• A significant institutional investor, Cormorant Asset Management, maintains a substantial stake, indicating continued confidence in BioAge Labs, Inc.'s prospects.
• The filing explicitly states the investment is for ordinary course business purposes, not for control-seeking, which can signal stability and a long-term investment horizon.

Negatives

• The filing itself does not present any explicit negative information regarding BioAge Labs, Inc. It is a disclosure of beneficial ownership.

Risks

• The filing does not detail specific risks related to BioAge Labs, Inc.'s operations or financial health; it is a disclosure of beneficial ownership.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from BioAge Labs, Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• This filing does not contain direct quotes or paraphrased statements from BioAge Labs, Inc. management.
• The reporting persons, Cormorant Asset Management, LP and Bihua Chen, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

StockSavvy.ai notes that a significant stake by an institutional investor like Cormorant Asset Management, known for its focus on healthcare and biotechnology, can be viewed positively by the market. Such an investment suggests a belief in the long-term potential of BioAge Labs, Inc., a company operating in the competitive and innovation-driven biotechnology sector. This continued ownership indicates a stable investment thesis from a specialized fund.

Comparison to Industry Standards

• StockSavvy.ai observes that a 5.69% stake is a substantial position for an institutional investor in a publicly traded company.
• While specific comparable companies or projects are not detailed in this filing, maintaining a stake above the 5% threshold typically signifies a meaningful, long-term investment rather than short-term trading.
• For instance, similar stakes by specialized biotech funds in companies like Moderna (MRNA) or BioNTech (BNTX) during their growth phases often preceded significant market attention and capital inflows, although the specific context and stage of BioAge Labs would require further analysis.

Stakeholder Impact

• Shareholders: The continued significant ownership by an institutional investor may instill confidence and potentially attract other investors, positively impacting share price stability and liquidity.
• Management: The presence of a large, specialized investor can provide a level of oversight and potentially influence strategic decisions, though the filing states no intent to influence control.

Next Steps

• The filing does not outline any specific future actions, events, or milestones for BioAge Labs, Inc. or the reporting persons beyond the ongoing beneficial ownership.

Key Dates

Recommendation

The filing indicates a significant, stable institutional investment in BioAge Labs, Inc. by Cormorant Asset Management, LP. While this is a positive signal of confidence, the filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily confirms an existing substantial stake, suggesting a 'hold' position for investors who may already be invested or are considering the stock, pending further operational updates from BioAge Labs.

Keywords

BioAge Labs, Cormorant Asset Management, Bihua Chen, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Healthcare